Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey


#30862

36pages

Assessment Group

$ 2999

In Stock

 

Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions. 

 

Patient progression reveals:

 

  • Decisions in treatment throughout patient stages
  • Factors influencing their decisions
  • Barriers to optimal care
  • Confidence in treatment.

 

Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Negative Metastatic Breast Cancer. 

 

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

 

This report allows you to:

 

  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance

 

Specific patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and xx. Oncologists who use a single agent were most likely to use x or x. Key factors in the choice of therapy include the following….

Table of Contents

 

Executive Summary

 

Chapter 1: Introduction

Table 1. Treatment Options in Triple Negative Metastatic Breast Cancer

 

Chapter 2: Respondent Demographics

Table 2. Eligibility Criteria for Survey Participation

Figure 2.1 Gender of Survey Respondents

Figure 2.2 Years since Medical School Graduation

Figure 2.3 Practice Settings

Figure 2.4 Practices in NCI Cancer Centers

Figure 2.5 Geographic Settings

Figure 2.6 Survey Respondents by State

Figure 2.7 Number of Physicians in Practice Groups

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

 

Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer

Choice of chemotherapy regimen, triple negative metastatic breast cancer

Figure 3.1

Single chemotherapy choices, triple negative metastatic breast cancer

Figure 3.2

Combination chemotherapy choices, triple negative metastatic breast cancer

Figure 3.3

Factors influencing treatment of triple negative metastatic breast cancer

Figure 3.4

Confidence managing patient with triple negative metastatic breast cancer

Figure 3.5

Other agents appropriate to include in treatment of triple negative metastatic breast cancer

Figure 3.1

Treatment of progressive triple negative metastatic breast cancer

Figure 3.2

Single chemotherapy agent, progressive triple negative metastatic breast cancer

Figure 3.3

Combination chemotherapy, progressive triple negative metastatic breast cancer

Figure 3. 4

Barriers to optimal treatment of progressive triple negative metastatic breast cancer

Figure 3.5

Changing therapy to manage neuropathy

Figure 3.6

Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.7

Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.8

Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.9

 

Chapter 4. Summary

Appendix A: Survey Instrument

NA

NA